The Satellite Meetings listed below are not part of the official ASAM Annual Conference as planned by its Program Committee. Attendance is optional, and in some cases, there is limited seating.
Learn About a Treatment Option for Patients with Moderate to Server Opioid Use Disorder
SPONSORED BY: INDVIOR
Friday, April 5, 2019 7:00 pm – 8:30 pm Hilton Orlando Lake Nona, Lobby Level
Dinner will be served.
PROBUPHINE® (buprenorphine) Implant REMS Training
SPONSORED BY: TITAN PHARMACEUTICALS
Friday, April 5, 2019 7:00 pm – 11:00 pm Hilton Orlando Lake Down, Lobby Level
Titan Pharmaceuticals will be conducting a PROBUPHINE (buprenorphine) Implant REMS Training in Orlando, FL on Friday, April 5, 2019 from [7:00pm – 11:00pm]. Training is strictly limited to Physicians and Advanced Practice Providers (i.e., nurse practitioners and physician assistants). Healthcare providers are asked to review the REMS materials and the Full Prescribing Information before attending.
Healthcare providers may certify in one of the following three roles:
Prescriber: only prescribes buprenorphine implant (must have a DATA2000 waiver)
Surgical Procedure provider: only performs the buprenorphine implant insertion and removal surgical procedures
Dual provider: both prescribes and performs the buprenorphine implant insertion and removal surgical procedures.
No spouses or guests are permitted to attend any part of the training.
This educational program is targeted to healthcare providers who specialize in the management of persons who use drugs (PWUD).
Educational Objectives: On completion of this activity, the participants should be better able to:
1. Discuss data on the incidence, prevalence and transmission of HCV in persons who use drugs (PWUD) 2. Describe the detrimental effects of chronic HCV, including the extrahepatic manifestations, to emphasize the need for diagnosis and treatment in PWUD 3. Discuss updates in screening mandates and treatment guidelines for HCV including the importance of harm reduction and prevention of reinfection. 4. Propose that HCV elimination is possible now that many prior HCV treatment obstacles have been removed
Faculty: Andrew H. Talal, MD, MPH Professor, Department of Medicine Director, Center for Research and Clinical Care in Liver Disease Jacobs School of Medicine and Biomedical Sciences University at Buffalo Buffalo, New York
Stevan A. Gonzalez, MD, MS Clinical Assistant Professor, Department of Internal Medicine Texas A&M College of Medicine Medical Director of Liver Transplantation Simmons Transplant Institute Baylor All Saints Medical Center Fort Worth, Texas
Agenda: 6:45 pm Epidemiology and Natural History 7:05 pm HCV Transmission, Screening, Diagnosis and Linkage to Care 7:25 pm HCV Management and Treatment Update 7:55 pm Q&A 8:15 pm Adjournment
Dinner will be served.
This activity is supported by an educational grant from AbbVie and Gilead
Accredited By: Annenberg Center for Health Sciences Provided By: The Chronic Liver Disease Foundation